CRNX

Crinetics Pharmaceuticals, Inc.

38.23

USD

CRNX Earnings Reports

Positive Surprise Ratio

CRNX beat 8 of 31 last estimates.

26%

Next Report

Date of Next Report

May 06, 2026

Estimate for Q1 26 (Revenue/ EPS)

$8.37M

-$1.27

Implied change from Q4 25 (Revenue/ EPS)

+35.86%

-1.55%

Implied change from Q1 25 (Revenue/ EPS)

+2218.72%

+22.12%

Crinetics Pharmaceuticals, Inc. earnings per share and revenue

On Feb 26, 2026, CRNX reported earnings of -1.29 USD per share (EPS) for Q4 25, beating the estimate of -1.39 USD, resulting in a 7.51% surprise. Revenue reached 6.16 million, compared to an expected 4.83 million, with a 27.48% difference. The market reacted with a -6.04% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 12 analysts forecast an EPS of -1.27 USD, with revenue projected to reach 8.37 million USD, implying an decrease of -1.55% EPS, and increase of 35.86% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Stevanato Group S.p.A.

Report Date

Mar 04, 2026 For Q4 25

Estimate

$0.17

Actual

$0.18

Surprise

+4.55%

Dyne Therapeutics, Inc. Common Stock

Report Date

Mar 02, 2026 For Q4 25

Estimate

-$0.77

Actual

-$0.76

Surprise

+2.28%

Amylyx Pharmaceuticals, Inc. Common Stock

Report Date

Mar 03, 2026 For Q4 25

Estimate

-$0.36

Actual

-$0.30

Surprise

+18.50%

Xeris Biopharma Holdings, Inc. Common Stock

Report Date

Mar 02, 2026 For Q4 25

Estimate

$0.04

Actual

$0.06

Surprise

+33.63%

Bioventus Inc. Class A Common Stock

Report Date

Mar 05, 2026 For Q4 25

Estimate

$0.21

Actual

$0.24

Surprise

+9.69%

Altimmune, Inc. Common Stock

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$0.24

Actual

-$0.27

Surprise

-10.16%

Aquestive Therapeutics, Inc. Common Stock

Report Date

Mar 04, 2026 For Q4 25

Estimate

-$0.13

Actual

-$0.26

Surprise

-92.31%

OmniAb, Inc. Common Stock

Report Date

Mar 04, 2026 For Q4 25

Estimate

-$0.09

Actual

-$0.11

Surprise

-21.82%

Profound Medical Corp. Common Stock

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$0.26

Actual

-$0.27

Surprise

-0.26%

MediWound Ltd.

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$0.64

Actual

-$0.56

Surprise

+13.08%

FAQ

What were Crinetics Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Crinetics Pharmaceuticals, Inc. reported EPS of -$1.29, beating estimates by 7.51%, and revenue of $6.16M, 27.48% above expectations.

How did the market react to Crinetics Pharmaceuticals, Inc.'s Q4 2025 earnings?

The stock price moved down -6.04%, changed from $43.74 before the earnings release to $41.10 the day after.

When is Crinetics Pharmaceuticals, Inc. expected to report next?

The next earning report is scheduled for May 06, 2026.

What are the forecasts for Crinetics Pharmaceuticals, Inc.'s next earnings report?

Based on 12 analysts, Crinetics Pharmaceuticals, Inc. is expected to report EPS of -$1.27 and revenue of $8.37M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.